From November 5 to 10, 2024, the 7th China International Import Expo (hereinafter referred to as "CIIE") will be held in Shanghai. This year marks the 30th anniversary of the founding of Fosun Pharma. As a "full-time student" of the 7th CIIE, Fosun Pharma will continue to work with global partners in the Medical Devices and Healthcare Exhibition Area of Hall 7.1 (Booth No.: 7.1B3-02) to demonstrate its strong strength and far-reaching influence in becoming a global leading medical innovation integrator.

Wu Yifang, Chairman of Fosun Pharma, said: "Over the past 30 years, Fosun Pharma has always insisted on innovation-driven development, actively embraced globalization, and deepened international cooperation. We are in sync with the development of the pharmaceutical industry and have demonstrated our innovative achievements and global strategic layout through the CIIE, an important platform for open cooperation. We will continue to promote global operations, accelerate the transformation of source innovation, and contribute to the grand blueprint of 'Healthy China'."

In the medical equipment and healthcare exhibition area, following the previous "Internet celebrity product" Da Vinci surgical robot, another "star product" of Intuitive Fosun, Ion bronchoscope robot, will make its debut at the CIIE after being approved for listing in China. In 2019, Ion was exhibited for the first time at the CIIE and became well-known to professionals and the public. At the end of 2022, Ion passed the review of the National Medical Products Administration and entered the "green channel" for innovative products. In March 2024, it successfully passed the approval of the National Medical Products Administration and was approved for listing. In September of the same year, the first Ion commercial installation was achieved and the first commercial application was successfully completed. It can be said that with the help of the "spillover effect" of the CIIE, Ion has completed the transformation from "exhibit" to "commodity".

Lung cancer is called the "number one killer" of cancer. In 2022, the number of new lung cancer cases in China reached 1.0606 million1. The 5-year survival rate of lung cancer patients is only 19.7%2. The five-year survival rate of patients with stage I lung cancer reached 77%-92%. "Early screening and early diagnosis" are crucial in improving the treatment effect of lung cancer. Bronchoscopy is one of the important means of early diagnosis of lung cancer, but because early lung nodules are usually located deep in the bronchi, it is difficult to identify and diagnose with existing technology. As the latest achievement of cutting-edge technology, the Ion bronchoscope operation control system has innovative performance in bronchial navigation operation control, which provides a new level of convenience and accuracy for clinical diagnosis and treatment, and can provide patients with new medical solutions. As of the third quarter of 2024, 736 Ions have been installed worldwide, and more than 150,000 Ion surgeries have been performed.

The cutting-edge development of global medical technology has brought new hope to patients with essential tremor and Parkinson's disease. At the upcoming 7th CIIE, the debut of the "Magnetic Wave Knife" V2 model is highly anticipated. This new model has obtained the European CE certification and the US FDA approval, and will formally submit a registration application to the China National Medical Products Administration (NMPA) in 2024. The innovation of the V2 model is that it can provide a non-invasive surgical treatment for essential tremor that is difficult to control with drugs clinically and Parkinson's disease with tremor as the main symptom. In addition, the ability to adapt to more brands and models of magnetic resonance equipment has greatly expanded the popularity and application of this technology.

The incidence of essential tremor in China is 0.9%, 4.6% for those over 65 years old, and the number of patients exceeds 10 million3; the prevalence of Parkinson's in people over 65 years old is 1.7%, and the number of patients exceeds 3.6 million4. The application of "magnetic wave knife" technology around the world has achieved remarkable results, successfully treating more than 20,000 patients with essential tremor and Parkinson's disease, and related clinical research results have been published in the top international journal "The New England Journal of Medicine" for three consecutive times5-7. This technology combines focused ultrasound and magnetic resonance imaging (MRI) for precise positioning, allowing high-intensity focused ultrasound to accurately ablate lesions and achieve treatment goals. This non-invasive treatment method not only reduces the patient's physical burden, but also reduces surgical risks and improves the safety and effectiveness of treatment.

The world's first 128-channel liquid helium-free magnetoencephalography device independently developed by Beijing Weici Technology, a strategic partner of Fosun Pharma, will also be exhibited. This innovative non-invasive brain functional imaging technology has created new ground for human brain science research and brain disease diagnosis and treatment. This also demonstrates Fosun Pharma's innovation in central nervous system (CNS) diagnosis and treatment solutions and its efforts in promoting the popularization of high-tech medical methods, bringing more efficient and accessible treatment options to patients with neurological diseases around the world.

In the 30 years since its establishment, Fosun Pharma has been patient-centric, focusing on unmet clinical needs, and continuing to deepen its core treatment areas such as solid tumors, hematological tumors, and immune inflammation. Thanks to the exhibition stage of the CIIE, Fosun Pharma's many innovative products and therapies have become more well-known. From exhibits to commodities, it has not only improved the accessibility of innovative drugs, but also benefited more Chinese patients.

As an old friend of the CIIE, the CAR-T cell therapy product Ikaida® (Akilencel Injection), which has been exhibited for the 7th consecutive year, shares the latest progress of "accessible and curable" in the field of lymphoma treatment every year. More than 110 city welfare insurances and more than 80 commercial insurances have opened up innovative payment paths for more patients; 170 Ikaida® high-standard treatment centers in 28 provinces, autonomous regions and municipalities across the country have treated more than 900 lymphoma patients; Ikaida® drug safety is at the international leading level.

A number of innovative products covering the treatment areas of tumors, autoimmunity, chronic diseases, etc. will continue to be unveiled, including the innovative drug Okonze® (netupitant palonosetron capsules), which is the world's first and so far the only dual-channel fixed-dose combination oral compound antiemetic preparation that simultaneously blocks NK-1 receptors and 5-HT3 receptors, providing a better solution for chemotherapy-induced nausea and vomiting in cancer patients; Fukoshu® (anti-human T-cell rabbit immunoglobulin) developed by Neovii has been approved in more than 50 countries for improving the prognosis of transplant patients, and has benefited more than 250,000 patients, solving major unmet needs.

In addition, the world's first phosphate absorption inhibitor, Ventilor® (tenapanol hydrochloride tablets), will be exhibited in China for the first time. Thanks to the open and compatible international platform and unique influence of the CIIE, the new third-generation COMT inhibitor, Ogenen® (opicapone), used to treat symptom fluctuations in adult Parkinson's disease patients, has taken a solid first step in its commercialization journey since the sixth CIIE officially announced its pilot in Boao Lecheng. The innovative products on display also include the world's first oral targeted drug for psoriasis, Otelostat® (apimilast tablets), the only peptide calcimimetic for the treatment of secondary hyperthyroidism in adult patients with chronic kidney disease receiving hemodialysis, and Ponbifo® (etelcatin hydrochloride injection), which will be fully presented to the audience.

The 30 years of Fosun Pharma are 30 years of continuous innovation and breakthroughs. Resonating with the Shanghai biopharmaceutical industry policy, Fosun Pharma has always been at the forefront of innovation, from introducing world-leading medical products to promoting localized production. Looking ahead, Fosun Pharma looks forward to leveraging the open platform of the CIIE to further promote the accessibility of innovative drugs and therapies and benefit more patients.

https://news.yaozh.com/archive/44413.html